

# Giovanni Ostuzzi

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8257844/publications.pdf>

Version: 2024-02-01

71  
papers

1,957  
citations

279798

23  
h-index

276875

41  
g-index

75  
all docs

75  
docs citations

75  
times ranked

2500  
citing authors

#	ARTICLE	IF	CITATIONS
1	Comparative efficacy and acceptability of psychotherapies for panic disorder with or without agoraphobia: systematic review and network meta-analysis of randomised controlled trials. <i>British Journal of Psychiatry</i> , 2022, 221, 507-519.	2.8	20
2	Esketamine for treatment-resistant depression in adults. <i>The Cochrane Library</i> , 2022, 2022, .	2.8	0
3	Effectiveness of a <scp>WHO</scp> self-help psychological intervention for preventing mental disorders among Syrian refugees in Turkey: a randomized controlled trial. <i>World Psychiatry</i> , 2022, 21, 88-95.	10.4	52
4	Comparing 1-year effectiveness and acceptability of once-monthly paliperidone palmitate and aripiprazole monohydrate for schizophrenia spectrum disorders: Findings from the STAR Network Depot Study. <i>Psychiatry Research</i> , 2022, 309, 114405.	3.3	10
5	Early pharmacological interventions for universal prevention of post-traumatic stress disorder (PTSD). <i>The Cochrane Library</i> , 2022, 2022, CD013443.	2.8	8
6	Preventing relapse in schizophrenia needs better evidence. <i>Lancet</i> , The, 2022, 399, 773-775.	13.7	4
7	Mapping the selection, availability, price and affordability of essential medicines for mental health conditions at a global level. <i>Epidemiology and Psychiatric Sciences</i> , 2022, 31, e22.	3.9	7
8	Factors Associated with Medication Adherence to Long-Acting Injectable Antipsychotics: Results from the STAR Network Depot Study. <i>Pharmacopsychiatry</i> , 2022, 55, 281-289.	3.3	6
9	Calling for policy actions to increase access to long-acting antipsychotics in low-income and middle-income countries. <i>Epidemiology and Psychiatric Sciences</i> , 2022, 31, e34.	3.9	3
10	Oral and long-acting antipsychotics for relapse prevention in schizophrenia spectrum disorders: a network meta-analysis of 92 randomized trials including 22,645 participants. <i>World Psychiatry</i> , 2022, 21, 295-307.	10.4	44
11	Cost-effectiveness of the Self-Help Plus Intervention for Adult Syrian Refugees Hosted in Turkey. <i>JAMA Network Open</i> , 2022, 5, e2211489.	5.9	6
12	Long-term effectiveness of Self-Help Plus in refugees and asylum seekers resettled in Western Europe: 12-month outcomes of a randomised controlled trial. <i>Epidemiology and Psychiatric Sciences</i> , 2022, 31, .	3.9	2
13	Continuing, reducing, switching, or stopping antipsychotics in individuals with schizophrenia-spectrum disorders who are clinically stable: a systematic review and network meta-analysis. <i>Lancet Psychiatry</i> , the, 2022, 9, 614-624.	7.4	28
14	Efficacy of interventions to reduce coercive treatment in mental health services: umbrella review of randomised evidence. <i>British Journal of Psychiatry</i> , 2021, 218, 185-195.	2.8	73
15	Comparing Long-Acting Antipsychotic Discontinuation Rates Under Ordinary Clinical Circumstances: A Survival Analysis from an Observational, Pragmatic Study. <i>CNS Drugs</i> , 2021, 35, 655-665.	5.9	14
16	Maintenance Treatment With Long-Acting Injectable Antipsychotics for People With Non-affective Psychoses: A Network Meta-Analysis. <i>American Journal of Psychiatry</i> , 2021, 178, 424-436.	7.2	54
17	A network meta-analysis of psychosocial interventions for refugees and asylum seekers with PTSD. <i>BMJ Global Health</i> , 2021, 6, e005029.	4.7	24
18	Effectiveness of Self-Help Plus in Preventing Mental Disorders in Refugees and Asylum Seekers in Western Europe: A Multinational Randomized Controlled Trial. <i>Psychotherapy and Psychosomatics</i> , 2021, 90, 403-414.	8.8	57

#	ARTICLE	IF	CITATIONS
19	Expanding access to long-acting antipsychotics in low-income and middle-income countries. <i>Lancet Psychiatry</i> , 2021, 8, 1034-1035.	7.4	4
20	The Role of Attitudes Toward Medication and Treatment Adherence in the Clinical Response to LAIs: Findings From the STAR Network Depot Study. <i>Frontiers in Psychiatry</i> , 2021, 12, 784366.	2.6	4
21	Which psychotherapy is effective in panic disorder? Findings and reflections from a systematic network meta-analysis. <i>European Psychiatry</i> , 2021, 64, S118-S118.	0.2	0
22	Safety of psychotropic medications in people with COVID-19. <i>European Psychiatry</i> , 2021, 64, S93-S93.	0.2	0
23	Efficacy of psychosocial interventions for mental health outcomes in low-income and middle-income countries: an umbrella review. <i>Lancet Psychiatry</i> , 2020, 7, 162-172.	7.4	163
24	Esketamine for treatment resistant depression: a trick of smoke and mirrors?. <i>Epidemiology and Psychiatric Sciences</i> , 2020, 29, e79.	3.9	28
25	Safety of psychotropic medications in people with COVID-19: evidence review and practical recommendations. <i>BMC Medicine</i> , 2020, 18, 215.	5.5	52
26	Tolerability and efficacy of vortioxetine versus SSRIs in elderly with major depression. Study protocol of the VESPA study: a pragmatic, multicentre, open-label, parallel-group, superiority, randomized trial. <i>Trials</i> , 2020, 21, 695.	1.6	8
27	Pharmacological treatment of hyperactive delirium in people with COVID-19: rethinking conventional approaches. <i>Therapeutic Advances in Psychopharmacology</i> , 2020, 10, 204512532094270.	2.7	21
28	Poor implementation of the EU clinical trial regulation is a major threat for pragmatic trials in European countries. <i>Epidemiology and Psychiatric Sciences</i> , 2020, 29, e126.	3.9	4
29	Clinical correlates of paliperidone palmitate and aripiprazole monohydrate prescription for subjects with schizophrenia-spectrum disorders: findings from the STAR Network Depot Study. <i>International Clinical Psychopharmacology</i> , 2020, 35, 214-220.	1.7	12
30	Esketamine clinical trials: reply to Maju et al.. <i>Epidemiology and Psychiatric Sciences</i> , 2020, 29, e122.	3.9	5
31	Introduction and methods of the evidence-based guidelines for the diagnosis and management of autism spectrum disorder by the Italian National Institute of Health. <i>Health and Quality of Life Outcomes</i> , 2020, 18, 81.	2.4	7
32	Safety of Psychotropic Medications in People With COVID-19: Evidence Review and Practical Recommendations. <i>Focus (American Psychiatric Publishing)</i> , 2020, 18, 466-481.	0.8	6
33	Reasons for initiating long-acting antipsychotics in psychiatric practice: findings from the STAR Network Depot Study. <i>Therapeutic Advances in Psychopharmacology</i> , 2020, 10, 204512532097810.	2.7	13
34	Which psychotherapy is effective in panic disorder? And which delivery formats are supported by the evidence? Study protocol for two systematic reviews and network meta-analyses. <i>BMJ Open</i> , 2020, 10, e038909.	1.9	3
35	Medicine-based evidence: the case of antidepressants in patients with coronary artery disease. <i>Epidemiology and Psychiatric Sciences</i> , 2019, 28, 18-20.	3.9	2
36	Antipsychotic use and risk of life-threatening medical events: umbrella review of observational studies. <i>Acta Psychiatrica Scandinavica</i> , 2019, 140, 227-243.	4.5	59

#	ARTICLE	IF	CITATIONS
37	Effectiveness and cost-effectiveness of Self-Help Plus (SH+) for preventing mental disorders in refugees and asylum seekers in Europe and Turkey: study protocols for two randomised controlled trials. <i>BMJ Open</i> , 2019, 9, e030259.	1.9	27
38	Efficacy and acceptability of psychosocial interventions in asylum seekers and refugees: systematic review and meta-analysis. <i>Epidemiology and Psychiatric Sciences</i> , 2019, 28, 376-388.	3.9	141
39	Early pharmacological interventions for preventing post-traumatic stress disorder (PTSD): a network meta-analysis. <i>The Cochrane Library</i> , 2019, , .	2.8	1
40	Beyond pain: can antidepressants improve depressive symptoms and quality of life in patients with neuropathic pain? A systematic review and meta-analysis. <i>Pain</i> , 2019, 160, 2186-2198.	4.2	18
41	Efficacy and acceptability of antidepressants in patients with ischemic heart disease. <i>International Clinical Psychopharmacology</i> , 2019, 34, 65-75.	1.7	15
42	Antidepressants for the treatment of depression in people with cancer. <i>The Cochrane Library</i> , 2018, 2018, CD011006.	2.8	66
43	Public health psychopharmacology: a new research discipline comes of age?. <i>Epidemiology and Psychiatric Sciences</i> , 2018, 27, 24-28.	3.9	2
44	Can a digital medicine system improve adherence to antipsychotic treatment?. <i>Epidemiology and Psychiatric Sciences</i> , 2018, 27, 227-229.	3.9	12
45	Prevalence and Correlates of Psychological Distress and Psychiatric Disorders in Asylum Seekers and Refugees Resettled in an Italian Catchment Area. <i>Journal of Immigrant and Minority Health</i> , 2018, 20, 263-270.	1.6	18
46	Antipsychotic drug exposure and risk of fracture. <i>International Clinical Psychopharmacology</i> , 2018, 33, 181-196.	1.7	22
47	Factors associated with first- versus second-generation long-acting antipsychotics prescribed under ordinary clinical practice in Italy. <i>PLoS ONE</i> , 2018, 13, e0201371.	2.5	44
48	New EMA report on paliperidone 3-month injections: taking clinical and policy decisions without an adequate evidence base. <i>Epidemiology and Psychiatric Sciences</i> , 2017, 26, 231-233.	3.9	15
49	Antipsychotic drug exposure and risk of myocardial infarction. <i>Epidemiology and Psychiatric Sciences</i> , 2017, 26, 18-21.	3.9	4
50	Combinations of QTc-prolonging drugs: towards disentangling pharmacokinetic and pharmacodynamic effects in their potentially additive nature. <i>Therapeutic Advances in Psychopharmacology</i> , 2017, 7, 251-264.	2.7	43
51	Regulatory meta-analyses for the evaluation of psychotropic medicines. <i>Lancet Psychiatry</i> , 2017, 4, 660-661.	7.4	3
52	Vortioxetine for depression in adults. <i>The Cochrane Library</i> , 2017, 2017, CD011520.	2.8	33
53	Antipsychotic combinations in schizophrenia. <i>Epidemiology and Psychiatric Sciences</i> , 2017, 26, 462-465.	3.9	2
54	Role of Co-occurring Alcohol and Substances Abuse on QTc Interval Prolongation Among Psychiatric Patients: A Cross-sectional National Survey. <i>European Psychiatry</i> , 2017, 41, S201-S202.	0.2	0

#	ARTICLE	IF	CITATIONS
55	Does formulation matter? A systematic review and meta-analysis of oral versus long-acting antipsychotic studies. <i>Schizophrenia Research</i> , 2017, 183, 10-21.	2.0	66
56	Mapping the evidence on pharmacological interventions for non-affective psychosis in humanitarian non-specialised settings: a UNHCR clinical guidance. <i>BMC Medicine</i> , 2017, 15, 197.	5.5	3
57	Common mental disorders in asylum seekers and refugees: umbrella review of prevalence and intervention studies. <i>International Journal of Mental Health Systems</i> , 2017, 11, 51.	2.7	238
58	Can We Identify the Active Ingredients of Behaviour Change Interventions for Coronary Heart Disease Patients? A Systematic Review and Meta-Analysis. <i>PLoS ONE</i> , 2016, 11, e0153271.	2.5	81
59	Prevalence and correlates of QTc prolongation in Italian psychiatric care: cross-sectional multicentre study. <i>Epidemiology and Psychiatric Sciences</i> , 2016, 25, 532-540.	3.9	46
60	First-generation antipsychotics and QTc: any role for mediating variables?. <i>Human Psychopharmacology</i> , 2016, 31, 313-318.	1.5	24
61	Implementation of treatment guidelines for specialist mental health care. <i>The Cochrane Library</i> , 2016, 12, CD009780.	2.8	29
62	Comparative effectiveness of long-acting antipsychotics: issues and challenges from a pragmatic randomised study. <i>Epidemiology and Psychiatric Sciences</i> , 2016, 25, 21-23.	3.9	6
63	Antipsychotic Dose Mediates the Association between Polypharmacy and Corrected QT Interval. <i>PLoS ONE</i> , 2016, 11, e0148212.	2.5	50
64	Antidepressants for the treatment of depression in people with cancer. <i>The Cochrane Library</i> , 2015, , CD011006.	2.8	70
65	Efficacy and acceptability of antidepressants on the continuum of depressive experiences in patients with cancer: Systematic review and meta-analysis. <i>Cancer Treatment Reviews</i> , 2015, 41, 714-724.	7.7	33
66	Beneficial and harmful consequences of prepartum and postpartum antidepressant exposure: Table 1. <i>Evidence-Based Mental Health</i> , 2014, 17, 69-71.	4.5	1
67	Autism spectrum disorders: weighing the risk of SSRI exposure in pregnancy. <i>Epidemiology and Psychiatric Sciences</i> , 2014, 23, 231-233.	3.9	3
68	Making the use of psychotropic drugs more rational through the development of GRADE recommendations in specialist mental healthcare. <i>International Journal of Mental Health Systems</i> , 2013, 7, 14.	2.7	10
69	Adverse effects of antipsychotic drugs: survey of doctors' versus patients' perspective. <i>Social Psychiatry and Psychiatric Epidemiology</i> , 2012, 47, 157-164.	3.1	15
70	SSRI plus supportive care more effective than supportive care alone for mild to moderate depression. <i>Evidence-Based Mental Health</i> , 2009, 12, 109-109.	4.5	5
71	Early pharmacological interventions for acute traumatic stress symptoms: a network meta-analysis. <i>The Cochrane Library</i> , 0, , .	2.8	1